The Role of Circulating Tumor DNA in Colon Cancer

A study conducted by the American Cancer Society found patients who were Black received worse care for colorectal cancer treatment, with health insurance is the leading cause of racial disparities.

Real-world patients with stage III colon cancer who were treated in the community practice setting with modified FOLFOX6 received less oxaliplatin vs historic controls from the phase 3 MOSAIC trial.

Phase 2/3 Study of Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients With Stage IIA Colon Cancer (COBRA): a first-in-kind trial seeks to provide level 1 evidence in evaluating the role of ctDNA as a guide for clinicians in the decision to administer adjuvant chemotherapy to patients with stage IIA colon cancer (NRG GI-005) (NCT04068103).

Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-US): a prospective phase 2/3 trial of MRD-based adjuvant therapy for patients with early-stage colon cancer with intensified and deintensified adjuvant therapy approaches using ctDNA status as a surrogate for MRD status (NRG-GI008) (NCT05174169).

Ibrahim Halil Sahin, MD, and colleagues, explore, the CIRCULATE-US (NRG-GI008; NCT05174169) investigating postoperative ctDNA dynamics in early-stage colon cancer for treatment selection.

Co-editor-in-Chief Howard S. Hochster, MD, highlights exciting clinical trials that may set future standards for adjuvant therapy selection in colon cancer.